Vicore Pharma has announced positive top-line data from the Angiotensin II Type Two Receptor Agonist Covid-19 Trial (ATTRACT) study of C21 (VP01) in hospitalised Covid-19 patients.

C21 is an orally available low molecular weight angiotensin II type 2 receptor (AT2R) agonist that activates the protective arm of the renin-angiotensin system (RAS).

The randomised, double-blind and placebo-controlled trial analysed the efficacy of oral C21 compared with placebo in 106 hospitalised Covid-19 patients with signs of an acute respiratory infection but not needing mechanical ventilation.

The patients randomly received oral treatment with C21 100mg or placebo for seven days along with the physician’s choice of standard of care.

According to the results, C21 reduced the risk of needing oxygen by 40% at the end of treatment.

As predefined in the Statistical Analysis Plan, the effect was statistically significant at the 10% level.

Moreover, one patient in the C21 group required mechanical ventilation as compared to four in the placebo group.

A trend for C21 reducing mortality was observed in the trial, with one death in the treatment group versus three in the placebo group.

Vicore Pharma CEO Carl-Johan Dalsgaard said: “Given the nature and scale of this study, we are surprised to see such a clear and significant clinical benefit for C21 and given the severity and duration of the pandemic, an oral C21 formulation with an excellent safety and tolerability profile could become an important and convenient early treatment of Covid-19, fulfilling a huge medical need.

“In addition, these results bode well for our ongoing study in idiopathic pulmonary fibrosis (IPF), as well as for future studies in larger indications where activation of AT2R may have a role to play.”